CXCL13 concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other neurological disorders determined by Luminex and ELISA

Cerar, 2013, Diagnostic value of cytokines and chemokines in Lyme neuroborreliosis, Clin. Vaccine Immunol., 20, 1578, 10.1128/CVI.00353-13 Dersch, 2015, The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis, Fluids Barriers CNS, 12, 12, 10.1186/s12987-015-0008-8 Fischer, 2009, CXCL13 and CXCL12 in central nervous system lymphoma patients, Clin. Cancer Res., 15, 5968, 10.1158/1078-0432.CCR-09-0108 Hansen, 2013, Lyme neuroborreliosis, Handb. Clin. Neurol., 115, 559, 10.1016/B978-0-444-52902-2.00032-1 Henningsson, 2016, Evaluation of two assays for CXCL13 analysis in cerebrospinal fluid for laboratory diagnosis of Lyme neuroborreliosis, APMIS, 124, 985, 10.1111/apm.12596 Huber, 2015, Targeting CXCL13 during neuroinflammation, Adv. Neuroimmune Biol., 6, 1, 10.3233/NIB-150101 Marra, 2010, CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis, Sex Transm. Dis., 37, 283, 10.1097/OLQ.0b013e3181d877a1 Millner, 1991, Lyme borreliosis of central nervous system (CNS) in children: a diagnostic challenge, Infection, 19, 273, 10.1007/BF01644966 Mygland, 2010, European Federation of Neurological Societies EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis, Eur. J. Neurol., 17, 8, 10.1111/j.1468-1331.2009.02862.x Pietikäinen, 2016, Cerebrospinal fluid cytokines in Lyme neuroborreliosis, J. Neuroinflamm., 13, 273, 10.1186/s12974-016-0745-x Rupprecht, 2009, The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis, J. Neuroinflamm., 6, 42, 10.1186/1742-2094-6-42 Rupprecht, 2014, CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine, Nervenarzt, 85, 459, 10.1007/s00115-014-4020-z Schmidt, 2011, A prospective study on the role of CXCL13 in Lyme neuroborreliosis, Neurology, 76, 1051, 10.1212/WNL.0b013e318211c39a Senel, 2010, The chemokine CXCL13 in acute neuroborreliosis, J. Neurol. Neurosurg. Psychiatry, 81, 929, 10.1136/jnnp.2009.195438 Stanek, 2011, Lyme borreliosis: clinical case definitions for diagnosis and management in Europe, Clin. Microbiol. Infect., 17, 69, 10.1111/j.1469-0691.2010.03175.x Stanek, 2014, Intrathecally produced IgG and IgM antibodies to recombinant VlsE VlsE-peptide, recombinant OspC and whole cell extracts in the diagnosis of Lyme neuroborreliosis, Med. Microbiol. Immunol., 203, 125, 10.1007/s00430-013-0322-1 Tjernberg, 2011, Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis, J. Infect., 62, 149, 10.1016/j.jinf.2010.11.005 Tumani, 1995, Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis, Neurology, 45, 1663, 10.1212/WNL.45.9.1663 van Burgel, 2011, Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid, J. Clin. Microbiol., 49, 2027, 10.1128/JCM.00084-11